These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21644042)

  • 1. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.
    Lahmer T; Knopf A; Lanzl I; Heemann U; Thuermel K
    Rheumatol Int; 2012 Aug; 32(8):2367-70. PubMed ID: 21644042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.
    Erckens RJ; Mostard RL; Wijnen PA; Schouten JS; Drent M
    Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):713-20. PubMed ID: 22119879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
    Santos G; Sousa LE; João AM
    An Bras Dermatol; 2013; 88(6 Suppl 1):26-8. PubMed ID: 24346872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
    Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
    Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
    Baughman RP; Lower EE; Drent M
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
    Thielen AM; Barde C; Saurat JH; Laffitte E
    Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.
    Milman N; Graudal N; Loft A; Mortensen J; Larsen J; Baslund B
    Clin Respir J; 2012 Oct; 6(4):238-47. PubMed ID: 22128762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis.
    Marcella S; Welsh B; Foley P
    Australas J Dermatol; 2011 Aug; 52(3):e8-11. PubMed ID: 21834808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: A meta-analysis.
    Rezaee M; Zangiabadian M; Soheili A; Calcagno TM; Rahmannia M; Dinparastisaleh R; Nasiri MJ; Mirsaeidi M
    Eur J Intern Med; 2023 Mar; 109():42-49. PubMed ID: 36526497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.
    Christoforidou A; Goudakos J; Bobos M; Lefkaditis E; Vital V; Markou K
    Am J Otolaryngol; 2013; 34(3):268-72. PubMed ID: 23357593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
    McDonnell MJ; Rutherford RM; O'Regan A
    J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sarcoidosis after adalimumab treatment in inflammatory rheumatic diseases: a report of two cases and literature review].
    Scailteux LM; Guedes C; Polard E; Perdriger A
    Presse Med; 2015 Jan; 44(1):4-10. PubMed ID: 25534463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature.
    Hasni SA; Kunz D; Finzel K; Gruber BL
    Spine (Phila Pa 1976); 2010 Aug; 35(18):E904-7. PubMed ID: 21381234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
    Lanternier F; Tubach F; Ravaud P; Salmon D; Dellamonica P; Bretagne S; Couret M; Bouvard B; Debandt M; Gueit I; Gendre JP; Leone J; Nicolas N; Che D; Mariette X; Lortholary O;
    Chest; 2013 Sep; 144(3):990-998. PubMed ID: 23744173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab.
    Bejerano C; Blanco R; González-Vela C; Agüero R; Carril JM; González-Gay MA
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S94-7. PubMed ID: 22410180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.